Development of adoptive immunotherapy using autologous dendritic cell pulsed with a RNF43 peptide in patients with advanced solid tumors

点击翻译按钮获取中文摘要

This is an open-label, Phase I study of adoptive immunotherapy using a RNF43 peptide in patients with advanced solid tumors which are confirmed that RNF43 are highly expressed. 7 patients with HLA-A* 2402 or HLA-A* 0201 were enrolled in this study. Of these, 5 patients completed all schedule. The primary end point was to assess safety of the treatment. No serious adverse event occurred in any patients and the treatment was considered to be tolerable. The secondary end point includes clinical response and it showed that 4 of 5 patients had stable disease(SD) and the level of tumor marker decreased in 2 of 4 SD patients. Immunological studies in these patients have been underway.